Back to Market返回行情
AZ
AZN.L AstraZeneca PLC
LSEHealthcare$13,400.00-2.91%OpenMarket Cap: $207.81B
As of 2026-06-01 11:15
Valuation
P/E (TTM)
26.70
PEG
—
P/B
5.90
P/S
4.59
EV/EBITDA
14.89
DCF Value
—
FCF Yield
3.1%
Div Yield
1.8%
Margins & Returns
Gross Margin
79.7%
Operating Margin
23.5%
Net Margin
17.2%
ROE
22.4%
ROA
9.2%
ROIC
12.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $15.29B | 82.5% | $4.25B | $3.08B | $1.97 | — |
| Q4 2025 | $15.50B | 79.9% | $2.98B | $2.33B | $1.49 | — |
| Q3 2025 | $15.19B | 81.2% | $3.58B | $2.53B | $1.62 | — |
| Q2 2025 | $14.84B | 75.2% | $3.51B | $2.52B | $1.61 | — |
| Q1 2025 | $13.96B | 76.4% | $3.78B | $3.00B | $1.92 | — |
| Q4 2024 | $14.54B | 67.7% | $1.99B | $1.46B | $0.94 | — |
| Q3 2024 | $13.96B | 71.1% | $2.87B | $1.47B | $0.94 | — |
| Q2 2024 | $12.98B | 75.7% | $2.85B | $1.93B | $1.24 | — |
| Q1 2024 | $12.55B | 75.2% | $3.21B | $2.16B | $1.38 | — |
| Q4 2023 | $12.25B | 72.6% | $1.31B | $978.1M | $0.63 | — |
| Q3 2023 | $11.05B | 73.1% | $1.93B | $1.32B | $0.85 | — |
| Q2 2023 | $11.55B | 74.2% | $1.82B | $1.84B | $1.18 | — |